ASRT - デポメッド (Assertio Therapeutics Inc.) デポメッド



symbol ASRT
会社名 Assertio Therapeutics Inc (デポメッド)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 デポメッド(Depomed Inc)専門製薬会社である。同社は疼痛および他の中枢神経系(CNS)疾患を主要治療対象とする。同社の製品はNUCYNTA ER(タペンタドール延長放出錠剤)、NUCYNTA IR (NUCYNTA)(タペンタドール)、Gralise(ガバペンチン)、CAMBIA(経口溶液用ジクロフェナクカリウム)、Zipsor(ジクロフェナクカリウム)、及びLazanda(フェンタニル)を含む。同社のNUCYNTA ER(タペンタドール延長放出錠剤)は成人における糖尿病性末梢神経障害に関連する神経因性疼痛を含む毎日の長期オピオイド治療が必要な疼痛管理製品で、NUCYNTA IR(タペンタドール)は大人の重度の急性痛に対する製品である。同社のGralise(ガバペンチン)はヘルペス後神経痛の1日1回製品である。CAMBIA(経口溶液用ジクロフェナクカリウム)は片頭痛発作の急性の治療のための製品である。   デポメッドは、痛みや中枢神経系疾患に焦点を当てた米国の製薬会社。主要薬品は、帯状疱疹後神経痛薬Gralise(ガバペンチン)急性の痛みを軽減する液体充填カプセルZipsor(ジクロフェナクカリウム)、成人のがん患者向け痛み止め薬鼻スプレ―Lazanda(フェンタニル)、偏頭痛薬CAMBIA(ジクロフェナクカリウム経口溶液)などを含む。   
本社所在地 7999 Gateway Boulevard Suite 300 Newark CA 94560 USA
電話番号 +1 224-419-7106
設立年月日 34912
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 434人
EBITDA EBITDA(百万ドル) 171.81900
終値(lastsale) 5.79
時価総額(marketcap) 370072285.14
時価総額 時価総額(百万ドル) 361.76320
売上高 売上高(百万ドル) 381.49800
企業価値(EV) 企業価値(EV)(百万ドル) 884.56820
当期純利益 当期純利益(百万ドル) -10.82000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Assertio Therapeutics Inc revenues increased less than 1% to $191.7M. Net income totaled $12.8M vs. loss of $53.4M. Revenues reflect Royalties and milestones increase from $387K to $5.5M also reflect Product Sales decrease of 63% to $71.2M. Net income reflects Selling general and administrative expe decrease of 40% to $55.5M (expense).



   Assertio Holdings: A Little More Risk, A Lot Higher Reward  2023/05/04 17:38:47 Seeking Alpha
Assertio acquired a future blockbuster which may likely generate sales by itself are more than half the current market cap. Read why ASRT stock is a strong buy.
   Artificial Intelligence Engine Predicts ASRT Stock to Gain 3% by June 1  2023/05/04 14:54:21 InvestorPlace
The world’s foremost artificial intelligence stock trading algorithm, An-E, predicts that Assertio (NASDAQ: ASRT ) stock will gain 3% by June 1. An-E (pronounced Annie) has made this kind of prediction before. Back in December, Wall Street was bullish on Johnson & Johnson (NYSE: JNJ ). Analysts were convinced JNJ could only go up… but An-E knew better. The algorithm said that JNJ stock was headed down 10% over one month… and JNJ stock fell that exact amount. Wall Street was shocked… but An-E saw it coming long before everyone else. We’ve seen spot-on predictions for Vontier (NYSE: VNT )… Martin Marietta Materials (NYSE: MLM )… Domino’s Pizza (NYSE: DPZ ). Now this technology has flagged a big move coming in Assertio over the next 21 days. Investors who pay close attention can maximize their profits… and protect their retirement savings like never before. That’s because An-E combines artificial intelligence and machine learning. And AI is at an inflection point right now. The team at TradeSmith has spent $18 million and 50,000 hours developing software for retail investors, but An-E is unlike anything we’ve ever built.
   Is the Assertio Holdings Inc. (NASDAQ:ASRT) stock an investment opportunity?  2023/05/02 16:40:00 US Post News
Assertio Holdings Inc. (ASRT)’s stock is trading at $5.90 at the moment marking a rise of 2.61% from the last session close. As of this writing, shares are priced at -15.71% less than their 52-week high of $7.00, and 217.20% over their 52-week low of $1.86. Based on the past 30-day period, the stock price […]
   Assertio Holdings Stock Is Still A Cheap Buy  2023/05/02 14:18:49 Seeking Alpha
Assertio Holdings stock fell 8.15% since my updated bullish thesis in March 2023, while the S&P 500 Index has gained 4.95%. See why we believe ASRT stock is a buy.
   SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ISEE, MDWT, ASRT  2023/05/02 13:07:00 GlobeNewswire
NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
   Assertio Holdings: Can Management Grow The Business? (NASDAQ:ASRT)  2022/11/15 16:53:23 Seeking Alpha
Management appears to have done a solid job putting Assertio''s troubled past behind. Click here to read my analysis of ASRT stock.
   Is Assertio Holdings Inc. (NASDAQ: ASRT) A Top Momentum Pick?  2022/11/12 15:30:00 Stocks Register
Assertio Holdings Inc. (NASDAQ:ASRT) price on Friday, November 11, rose 5.71% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $2.96. A look at the stock’s price movement, the close in the last trading session was $2.80, moving within a range at $2.81 and $2.97. The beta value … Is Assertio Holdings Inc. (NASDAQ: ASRT) A Top Momentum Pick? Read More »
   Today’s watch list includes Assertio Holdings Inc. (NASDAQ:ASRT) stock  2022/11/10 18:24:00 US Post News
Assertio Holdings Inc. (ASRT)’s stock has witnessed a price hike of 4.49% from the previous close with its current price standing at $2.79. Its current price is -37.16% under its 52-week high of $4.44 and 134.43% more than its 52-week low of $1.19. Based on the past 30-day period, the stock price is -0.36% below […]
   Assertio Holdings Inc. (NASDAQ: ASRT) Shares Rose Recently, But Trouble Could Still Be Around The Corner.  2022/11/09 18:00:00 Stocks Register
Assertio Holdings Inc. (NASDAQ:ASRT) price is hovering higher on Wednesday, November 09, jumping 3.44% above its previous close. A look at today’s price movement shows that the recent level at last check reads $2.62, with intraday deals fluctuating between $2.58 and $2.70. The company’s 5Y monthly beta was ticking 1.49 while its P/E ratio in … Assertio Holdings Inc. (NASDAQ: ASRT) Shares Rose Recently, But Trouble Could Still Be Around The Corner. Read More »
   Assertio Therapeutics PT Raised to $6.75 at Roth Capital  2022/11/09 08:54:03
   Should You Expect Assertio Holdings Inc. (NASDAQ:ASRT) To Recover From Its 73.27% Gain From Highs?  2022/07/07 15:30:00 Marketing Sentinel
Assertio Holdings Inc. (NASDAQ:ASRT)’s traded shares stood at 1.47 million during the last session, with the company’s beta value hitting 1.49. At the close of trading, the stock’s price was $3.18, to imply a decrease of -2.75% or -$0.09 in intraday trading. The ASRT share’s 52-week high remains $3.52, putting it -10.69% down since that … Should You Expect Assertio Holdings Inc. (NASDAQ:ASRT) To Recover From Its 73.27% Gain From Highs? Read More »
   Assertio Holdings: Management Still Swimming Against The Tide  2022/06/10 17:17:56 Seeking Alpha
Assertio, formerly DepoMed, nearly went under after a disastrous acquisition of opioid drug Nucynta. Has the tide turned for the biotech? Read why investors should steer clear of Assertio.
   7 Best Penny Stocks to Buy Now for Moonshot Potential  2022/06/10 10:25:53 InvestorPlace
Finding stocks with a moonshot potential is like finding gold — you must know where to search, what criteria to use in a stock screener and how to make a narrow list of selections from that info. Even the best penny stocks to buy now are riskier than large-cap or mid-cap stocks. But while this is true, it is often a bad idea to neglect good penny stocks (and their potential for big gains). If you’re looking to expand into penny stocks, I have a few top picks to share with you. But first, what does moonshot potential mean? I would say that a return relatively higher than the average U.S. stock market return during the past 10 years meets the definition of a moonshot potential. I am not referring to a 100% increase but to be less realistic to return that is higher than the 28.7% gains of the S&P 500 in 2021 . For example, 40% or 50% would be a great return. 7 Top-Rated Large-Cap Stocks to Buy and Hold Can the best penny stocks to buy now move even higher? I would say yes, but don’t throw everything at them.
   Investment Analysts'' Weekly Ratings Changes for Assertio  2022/06/07 13:03:08 Business Mag
Several analysts have recently updated their ratings and price targets for Assertio : 6/6/2022 - Assertio was downgraded by analysts at from a “strong-buy” rating…
   Assertio Holdings, Inc. to Participate in LD Micro Invitational XII Conference  2022/06/01 12:30:00 GlobeNewswire
LAKE FOREST, Ill., June 01, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced its participation in the LD Micro Invitational XII Conference on June 7-9, 2022. The conference is being held at the Four Seasons Hotel Westlake Village near Los Angeles, CA. This will be an in-person conference with Assertio presenting on Wednesday, June 8, 2022, at 3:00 pm pacific time in Track 1 and hosting 1:1 meetings with investors throughout the day.

 関連キーワード  (医薬品 米国株 デポメッド ASRT Assertio Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)